BioNexus Gene Lab Corp (BGLC) stock
BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 19, 2026Score 4/30
$0.68+0.00 (0.00%)
Close on Nov 20, 2026Market cap $1.99MP/E –Yield –
BioNexus Gene Lab shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
BioNexus Gene Lab's shares outstanding was 3M at Sep 30, 2026. For fiscal 2024 it was 18M, up 12.2% from the year before. The highest annual figure on record is 103M in fiscal 2020.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 18M | +12.2% |
| FY2023 | Dec 31, 2023 | 16M | -84.6% |
| FY2020 | Dec 31, 2020 | 103M | +19.2% |
| FY2019 | Dec 31, 2019 | 86M | +30.2% |
| FY2018 | Dec 31, 2018 | 66M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 3M | +49.9% |
| Q2 FY2026 | Jun 30, 2026 | 2M | +34.5% |
| Q1 FY2026 | Mar 31, 2026 | 2M | +34.5% |
| Q3 FY2025 | Sep 30, 2025 | 2M | +1.7% |
| Q2 FY2025 | Jun 30, 2025 | 2M | -89.8% |
| Q1 FY2025 | Mar 31, 2025 | 2M | -99.0% |
| Q3 FY2024 | Sep 30, 2024 | 2M | -99.0% |
| Q2 FY2024 | Jun 30, 2024 | 2M | -99.0% |
| Q1 FY2024 | Mar 31, 2024 | 18M | -82.9% |
| Q3 FY2021 | Sep 30, 2021 | 171M | +66.7% |
| Q2 FY2021 | Jun 30, 2021 | 171M | +66.7% |
| Q1 FY2021 | Mar 31, 2021 | 171M | +66.7% |
| Q4 FY2020 | Dec 31, 2020 | 103M | -1.1% |
| Q3 FY2020 | Sep 30, 2020 | 103M | +28.0% |
| Q2 FY2020 | Jun 30, 2020 | 103M | +37.6% |
| Q1 FY2020 | Mar 31, 2020 | 103M | +37.6% |
| Q4 FY2019 | Dec 31, 2019 | 105M | +65.5% |
| Q3 FY2019 | Sep 30, 2019 | 80M | +19.2% |
| Q2 FY2019 | Jun 30, 2019 | 75M | – |
| Q1 FY2019 | Mar 31, 2019 | 75M | – |
| Q4 FY2018 | Dec 31, 2018 | 63M | – |
| Q3 FY2018 | Sep 30, 2018 | 67M | – |
See a number that looks wrong?